MedTrace Logo

cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC

NCT05025592 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-09-02

No results posted yet for this study

Summary

explore the effectiveness and safety of conventional transarterial chemoembolization (cTACE) or transarterial chemoembolization (DEB-TACE) plus hepatic arterial Infusion chemotherapy (HAIC) combined with regorafenib and anti-PD-1 antibody or not for unresected hepatocellular carcinoma (uHCC)

Conditions

  • HCC
  • Transarterial Chemoembolization
  • Hepatic Arterial Infusion Chemotherapy
  • Regorafenib

Interventions

DRUG

Regorafenib

patients will received TACE-HAIC and regorafenib and anti-PD1 antibody or not

DEVICE

cTACE/DEB-TACE-HAIC

conventional transarterial chemoembolization(cTACE)/transarterial chemoembolization (DEB-TACE) plus hepatic artery infusion

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-10
Primary Completion
2022-12-31
Completion
2022-12-31
FDA Drug
Yes
FDA Device
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05025592 on ClinicalTrials.gov